Remember meForgot password?
    Log in with Twitter
Press Release

Oct 2, 2020 12:24 UTC

Cystic Fibrosis (CF) Pipeline Insight Report 2020 -

DUBLIN--(Business Wire)--The "Cystic Fibrosis (CF) - Pipeline Insight, 2020" drug pipelines has been added to's offering.

This Cystic Fibrosis (CF) - Pipeline Insight, 2020, report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Cystic Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cystic Fibrosis Emerging Drugs Chapters

This segment of the Cystic Fibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cystic Fibrosis Emerging Drugs

MRT5005: Translate Bio

MRT5005 is the first clinical-stage mRNA product candidate designed to address the underlying cause of CF by delivering mRNA encoding fully functional cystic fibrosis transmembrane conductance regulator (CFTR) protein to the lung epithelial cells through nebulization. MRT5005 is being developed to treat all patients with CF, regardless of the underlying genetic mutation, including those with limited or no CFTR protein. This mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020.

Cystic Fibrosis: Therapeutic Assessment

This segment of the report provides insights about the different Cystic Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cystic Fibrosis

There are approx. 50+ key companies which are developing the therapies for Cystic Fibrosis. The companies which have their Cystic Fibrosis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, SolAeroMed Inc., Eloxx Pharmaceuticals, Inc., Corbus Pharmaceuticals Inc., Laurent Pharmaceuticals Inc. etc.


This report covers around 50+ products under different phases of clinical development like

  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Oral
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecules
  • RNA
  • Gene therapies
  • Immunotherapies
  • Vaccines
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cystic Fibrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cystic Fibrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cystic Fibrosis drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Cystic Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Cystic Fibrosis.
  • In September 2020, the FDA has granted MRT5005 both orphan drug and fast track designation for the treatment of cystic fibrosis

Cystic Fibrosis Report Insights

  • Cystic Fibrosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Cystic Fibrosis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Cystic Fibrosis drugs?
  • How many Cystic Fibrosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cystic Fibrosis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cystic Fibrosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cystic Fibrosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • AbbVie
  • Allergan PLC
  • Chiesi Farmaceutici SpA
  • F. Hoffmann-La Roche AG
  • Gilead Sciences
  • Novartis AG
  • Pharmaxis Ltd
  • PTC Therapeutics
  • Vertex Pharmaceuticals Incorporated
  • Novoteris, LLC
  • Neupharma Srl
  • AlgiPharma AS
  • Arrowhead Pharmaceuticals
  • Eloxx Pharmaceuticals, Inc.

Key Products

  • Teicoplanin
  • MRT5005
  • Inhaled AR-501
  • ARO-ENaC
  • OligoG DPI
  • ELX-02
  • POL6014
  • CB-280
  • S-1226
  • Ivacaftor

For more information about this drug pipelines report visit
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Latest News
Top News